Shares of Cytori Therapeutics (CYTX) were buoyed by the news that European regulators have approved its stem cell technology for a range of procedures including breast reconstruction surgery and tissue repair.
Cytori's Celution system is designed to extract stem cells from a person's fat tissue so they can be used to create a graft that can be used in the repair work. Just last spring Cytori touted mid-stage data for its adult stem cell therapy for heart damage.
"The expanded indications improve our ability to provide the Celution System to European hospitals in addition to the private-pay plastic and cosmetic surgery clinics," said Marc Hedrick, president of Cytori. "These claims, coupled with our expanded focus on reimbursement, will make this technology more broadly available, not just for a wider range of procedures but to a greater population of patients."
- here's the Cytori release
- and here's the Reuters report